In the next issue, we take a look at regulatory process and access barriers for ‘first generics’ – the first-to-market generic versions of innovator products. We will also track the latest news on the fentanyl crisis, and upcoming RSV vaccines.
EDITORIAL
Editor |Manasi Vaidya
Writers | Akosua Mireku, William Newton, Natasha Spencer-Jolliffe, Sally Turner, Adam Zamecnik, Urte Fultinaviciute
Editor - Thematic Take | Lara Virrey
Graphic Designers | Anett Arc, Noemi Balint, Will Ingham
Publisher | Susanne Hauner
ADVERTISING
Sales Manager | Tom McCormick
+44 207 8669440
Cover image credit: Emily Wyatt, Mark Davis, California Institute of Technology
Copyright 2023 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.